ReviewAddiction (Abingdon, England)2022
Clinical management of cannabis withdrawal.
Review in Addiction (Abingdon, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025Pooled it
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- Cannabinoid use generalizes stress responses: involvement of astrocyte plasticity and activation of matrix metalloproteinases in the nucleus accumbens core.Molecular psychiatry · 2026Article
- Cue-elicited prefrontal gamma-aminobutyric acid (GABA) dynamics in cannabis use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Cannabis use and beliefs among people in recovery from substance use disorders.Journal of cannabis research · 2026Article
- Beyond abstinence: Redefining success in cannabis use disorder treatment.Addiction (Abingdon, England) · 2026Article
- Consumption patterns and withdrawal symptoms in dual cannabis-tobacco users in Spain: Cross-sectional study.Addictive behaviors reports · 2026Article
- Not just neurons: glial mechanisms driving sex-specific vulnerability to withdrawal and relapse in substance use disorder.Frontiers in neuroendocrinology · 2026Review
- Article
- Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.Cureus · 2025Review
- The unmet need for cannabis use disorder treatment in multiple sclerosis: Insights from a nationwide pilot study.Multiple sclerosis and related disorders · 2025Article
- Cannabis use and cannabis use disorders and their treatment in the Europe.European archives of psychiatry and clinical neuroscience · 2025Review
- Effectiveness of cannabis use and cannabis use disorder interventions: a European and international data synthesis.European archives of psychiatry and clinical neuroscience · 2025Review
- Brain Function Outcomes of Recent and Lifetime Cannabis Use.JAMA network open · 2025Article
- Cannabis use patterns, motivations, and reasons for abstinence in pregnancy.Frontiers in psychiatry · 2025Article
- Case Report: Substance fixation in autism spectrum disorder with resultant anorexia nervosa.Frontiers in psychiatry · 2025Article
- Budtender Perceptions and Knowledge of Cannabis and Mental Health: A Preliminary Study.Cannabis (Albuquerque, N.M.) · 2025Article
- Clinical Evaluation of the Cannabis-Using Patient: A Moving Target.The Permanente journal · 2024Review
- Considerations for Anesthesia in Older Adults with Cannabis Use.Drugs & aging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsCannabis withdrawal is a well-characterized phenomenon that occurs in approximately half of regular and dependent cannabis users after abrupt cessation or significant reductions in cannabis products that contain Δ
methodsNarrative review of literature.
resultsSymptom onset typically occurs 24-48 hours after cessation and most symptoms generally peak at days 2-6, with some symptoms lasting up to 3 weeks or more in heavy cannabis users. The most common features of cannabis withdrawal are anxiety, irritability, anger or aggression, disturbed sleep/dreaming, depressed mood and loss of appetite. Less common physical symptoms include chills, headaches, physical tension, sweating and stomach pain. Despite limited empirical evidence, supportive counselling and psychoeducation are the first-line approaches in the management of cannabis withdrawal. There are no medications currently approved specifically for medically assisted withdrawal (MAW). Medications have been used to manage short-term symptoms (e.g. anxiety, sleep, nausea). A number of promising pharmacological agents have been examined in controlled trials, but these have been underpowered and positive findings not reliably replicated. Some (e.g. cannabis agonists) are used 'off-label' in clinical practice. Inpatient admission for MAW may be clinically indicated for patients who have significant comorbid mental health disorders and polysubstance use to avoid severe complications.
conclusionsThe clinical significance of cannabis withdrawal is that its symptoms may precipitate relapse to cannabis use. Complicated withdrawal may occur in people with concurrent mental health and polysubstance use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.